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Abstract
Background: The aim of this study was to evaluate the impact of Quality and Outcomes Framework (QOF), a major pay-for-
performance programme in the United Kingdom, on prescribing of long-acting reversible contraceptives (LARC) in primary
care.
Methods: Negative binomial interrupted time series analysis using practice level prescribing data from April 2007 to March
2012. The main outcome measure was the prescribing rate of long-acting reversible contraceptives (LARC), including
hormonal and non hormonal intrauterine devices and systems (IUDs and IUSs), injectable contraceptives and hormonal
implants.
Results: Prescribing rates of Long-Acting Reversible Contraception (LARC) were stable before the introduction of
contraceptive targets to the QOF and increased afterwards by 4% annually (rate ratios = 1.04, 95% CI = 1.03, 1.06). The
increase in LARC prescribing was mainly driven by increases in injectables (increased by 6% annually), which was the most
commonly prescribed LARC method. Of other types of LARC, the QOF indicator was associated with a step increase of 20%
in implant prescribing (RR = 1.20, 95% CI = 1.09, 1.32). This change is equivalent to an additional 110 thousand women
being prescribed with LARC had QOF points not been introduced.
Conclusions: Pay for performance incentives for contraceptive counselling in primary care with women seeking
contraceptive advice has increased uptake of LARC methods.
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Introduction
Long-acting reversible contraception (LARC) is highly clinically
effective compared with more widely used short term contracep-
tive methods. LARC is defined as ‘methods that require
administering less than once per cycle or month[1], including
non-hormonal Intrauterine Devices (Copper-IUD); hormonal
IUD or Intrauterine Systems (IUS), also known as Levonorgestrel
intrauterine systems(LNG-IUS); injectable contraceptives and
hormonal implants. LARC has lower failure rates of ,1% with
typical use than oral contraceptive pills or condoms (8% and 15%
respectively), partly due to easier compliance [2,3] and becomes
more cost-effective after the first year [1,4–6]. Although LARC
methods such as copper-intrauterine devices (copper-IUDs) are the
most commonly used non-permanent contraceptives in the world,
the use of LARC including IUDs is lower in many developed
countries including the United Kingdom (UK) and the United
States (US), both of which have high unintended pregnancy
rates[7–10].
Recently in the UK, several government initiatives have aimed
to increase awareness and use of LARC including public policy
initiatives such as National Institute for Health and Clinical
Excellence (NICE) LARC guidelines and Quality and Outcome
Framework (QOF)[1,11]. The pay-for-performance programme,
implemented in April 2004 by the National Health Services
(NHS), linked GP income to performance against targets set in
QOF indicators [12]. A new set of Quality and Outcome
Framework (QOF) indicators on contraception was introduced
in the 2009-10 General Medical Services (GMS) contract for
General Practices. Unlike previous years’ QOF indicators in
sexual health (CON1 and CON2) where the focus was only on
having a policy for emergency contraception requests and
provision of pre-conceptual advice[13]. Sexual health indicators
(SH1, SH2, SH3) introduced in April 2009 focused on provision of
information on long acting reversible methods of contraception to
women attending for contraceptive advice[11] aimed at increasing
awareness of LARC methods among women seeking contraceptive
advice in general.
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Previous studies evaluating the impact of QOF on care quality
and health outcomes across different chronic disease areas have
reported mixed results and several studies suggest improvements
predate the QOF [14–17]. There is little evidence assessing the
impact of QOF implementation on contraceptive provision. This
study investigates the impact of QOF contraceptive incentives on
LARC uptake by examining LARC prescribing patterns in
primary care before and after the introduction of QOF
contraception indicators in 2009.
Methods
Data
Data used in this study were obtained from the Prescription
Pricing Authority (PPA) which is the main source of information
on general practitioners’ prescribing in England. The specific data
record we used is the Prescribing Analysis and Cost (PACT) data
which records all NHS prescriptions issued by general practition-
ers and dispensed by pharmacists and has been widely used for
research[18].
We obtained quarterly prescribing data from a random sample
of 581 general practices in England from April 2007 to March
2012. Our sample can be seen as nationally representative, as we
compared our sample practices with the national data for practice
characteristics including the registered female population 15 to 44
years old, locality (urban/rural), deprivation (Index of Multiple
Deprivation), number of GPs and number of female GP and
ethnicity (percentage of White British registered population) and
found no statistically significance between our sample and the
population except for the ethnicity in which the national average
was 80% compared with 71% in our sample.
To preserve confidentiality, the PPA was not able to supply data
from single-handed practices. NHS prescribing outside of general
practices including prescriptions from hospitals that were dis-
pensed in the community, prescriptions dispensed in hospitals or
mental health units and private prescriptions were not included.
We grouped contraceptive prescribing data as combined oral
contraceptive pills (COCs), progestogen-only pills (POPs), inject-
ables, Intra-uterine devices (IUDs) copper and progestogen-
containing, implants, diaphragm and caps, spermicides, contra-
ceptive patches, vaginal rings and emergency hormonal contra-
ceptives (EHC). EHC were excluded from the analysis as our main
outcome of interest was on-going use of contraceptives not
emergency use. We defined LARC as IUDs, implants and
injectables and non-LARC consists of COCs, POPs, diaphragms
and caps.[19]
Outcome measure
Our primary outcome measure was the rate of GP prescribed
LARCs to their registered population. The basic measure of
volume is the number of prescription items, where items refer to a
single item on a prescription form. To enable comparison between
LARC and non-LARC items, namely COCs, and POPs, we
transformed the items into annual prescribed units for patients.
We adjusted prescribing rates converting monthly prescriptions to
equivalent items per annum for COCs and POP and 4 injectable
items per annum (since these are administered every 3 months).
LARC methods were assumed to be one item per patient. We
calculated contraceptives prescribed per 1000 registered female
population aged 15–44 years to account for variation between
practices.
Statistical analyses
We used a negative binomial interrupted time-series (ITS)
method to estimate changes in levels and trends in prescribing of
LARCs after of the QOF contraceptive services incentives were
implemented. While taking into account the overall time trend,
this model estimates both the immediate change and change in
time trend after the policy implementation [15,20–24]. To
account for unobserved heterogeneity for general practice, we
fitted our data using a random effect model. We calculated
changes in prescribing rate ratio (RR) which is the ratio of the
actual prescribing rate in relation to the rate projected by the
underlying trend.
Our model was adjusted for underlying time trend (continuous
variable for each quarter), seasonal effect (dummy variables for
quarters in financial year), geographical region (dummy variable
for PCTs), ethnicity, residence (urban/rural) and socioeconomic
index for each practice. We used the Index of Multiple
Deprivation (IMD), provided by the Department of Communities
and Local Government as a deprivation measure, deriving
categorical quintiles of deprivation for IMD where the highest
quintile was set as the most deprived. We derived a measure of
rurality for each practice location based on population density of
the practice postcode calculated from the 2001 census by Office
for National Statistics (ONS). We also included in our model the
presence of at least one female GP in the practice as a dummy
variable, since having a female GP selectively increases provision
of methods such as IUDs [25,26].
We estimated number of additional LARC prescriptions after
the implementation of QOF by estimating the number of
prescription in the absence of the policy (the counterfactual). To
do this, we used the coefficient estimated in the model but setting
the policy dummy and time after the policy variables to zero for
the whole time period, then adding the differences in number of
prescription each quarter between the actual prescription and
counterfactual estimate.
We tested for multicollinearity for covariates controlled for in
our analysis. The multicollinearity diagnostics (VIF) were all less
than 5, indicating that multicollinearity was not a problem. We
tested for linearity of the time trend and added a quadratic term
for the time variable when the linearity of the time trend was not
met. Additionally, we conducted a sensitivity analysis to assess
whether any changes in prescribing were also found in non-
LARCs items. We performed all statistical analyses using Stata 11
(StataCorp).
Results
There was wide variation across practices in the numbers of
contraceptives prescribed, numbers of registered women aged 15
to 44 years and QOF achievements. The mean number of
registered patients per practice was 1577 (range 54 to 8868) and
mean QOF contraception achievement in 2010-11 was 82%
(range 0 to 100%) and 89% (range 0 to 100%) in 2011-12. The
most commonly prescribed contraceptives were COCs at 38 per
1000 registered women aged 15 to 44 years (range 0 to 122),
followed by injectables, POPs, implants and IUS, at 17 (range 0 to
182), 13 (range 0 to 51), 2 (range 0 to 44) and 2 (0 to 30),
respectively. Copper-IUDs (IUCD) were the least commonly
prescribed LARCs in the primary care at 1 per 1000 registered
females aged 15–44 years (range 0 to 13).
Prescribing rates before and after QOF
LARC prescribing was stable prior to April 2009, with a
decreasing gradient of 20.4% annually (Table 1). This changed to
Pay for Performance on LARC
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an increasing trend in LARC prescribing of 4% annually (adjusted
rate ratio = 1.04, 95% CI= 1.03, 1.06) after the introduction of
QOF contraception incentives. Overall, the mean number of
LARC prescribed by practices increased by 10% in the 4 years
after-QOF contraception indicators were implemented compared
to the pre-QOF baseline in 2008-09. Of the main LARC methods
we found prescribing of implants increased substantially by 88%
whilst IUS, injectable, IUCD and increased by 27%, 8%, and 8%
respectively (Figure 1).
The increase in LARC prescribing was driven by increases in
injectables, which were the most commonly prescribed LARC
method. Injectables increased by 6% annually (RR= 1.06, 95%
CI= 1.04, 1.08) in the post-QOF period against a decreasing
secular trend 22.4% (RR= 0.98, 95% CI= 0.96, 0.99). There
was a step change in prescribing rate of implants, which increased
by 20% increase (RR= 1.20, 95% CI= 1.09, 1.32) immediately
after the QOF indicators were introduced. The trend change
(RR=1.34, 95% CI=1.13, 1.58) suggested that there was a
sustained increase in implants prescribing in the post-QOF period
when compared to the pre-QOF period.
The oral contraceptive prescribing rate was increasing by 1.4%
(RR= 1.01, 95% CI 1.01, 1.02) before QOF and decreased by
1.2% annually (RR= 0.99, 95% CI= 0.98, 0.99) in the post-
QOF implementation period. POPs prescribing rates were
increasing by 12% (RR= 1.12, 95%CI= 1.11, 1.13) before
QOF implementation then decreased by 3% annually after-
wards(RR= 0.97, 95% CI= 0.97, 0.98). The COCs prescribing
rate remained the same with a 2% decreasing trend before and
after QOF.
Practice characteristics associated with LARC prescribing
GPs in urban practices were less likely to prescribe LARC
methods than rural GPs, by 23% (RR= 0.77, 95% CI= 0.66 to
0.91), and this was most significant for implants, IUS and IUCD
methods, 57% (RR= 0.43, 95% CI= 0.35, 0.54), 45% (RR=
0.55, 95% CI= 0.42, 0.72) and 55% (RR= 0.45, 95% CI= 0.32,
0.64) respectively. The presence of one or more female GPs in a
practice was associated with a doubling in LARC prescribing
compared to those with no female GP in the practice (RR=2.03,
95% CI= 1.82, 2.27). This was particularly significant for IUCD
and implants (RR= 2.26, 95% CI= 1.76, 2.90; and 2.40, 95%
CI= 1.95 to 2.97 respectively).
Discussion
Prescribing rates of LARC methods increased by 4% annually
after the QOF contraceptive indicators were implemented. This
increase is equivalent to 8700 more women being prescribed with
LARC (1100 in the first year, 3200 and 4400 in the second and
third year) after the implementation of QOF contraception
incentives. Extrapolating this effect to the nationally registered
population of women aged 15 to 44 years this is equivalent to an
additional 110 thousand women who would have been prescribed
LARC. The increase was accompanied by falls in oral contracep-
tive pill prescribing indicating there might have been a switch to
long term contraceptive methods during the post-QOF period.
Strengths and weaknesses in relation to other studies
This study is the first to investigate the impact of QOF on
contraceptive provision. The interrupted time series method that
we used disentangled the secular time trend from the effect of the
QOF. We found no published studies on contraceptive prescribing
trends during the time frame of the observed LARC increases
against which to validate our estimates. Previous studies evaluating
the effectiveness of QOF on prescribing of other drugs have shown
similar increases in the volume of prescribing after the introduc-
tion of the QOF in both England and Northern Ireland compared
to the period before[27]. Some have suggested that QOF may
have rewarded and reinforced existing prescribing behaviours
[28]. Our findings are congruent with several previous studies on
the impact of QOF showing an immediate impact of QOF, which
then plateaued [14–16] [29–32]. However there are a number of
important limitations relating to data quality and completeness.
Routinely collected data from PACT is not subject to quality
control for research purposes and we did not carry out any internal
validation. As with any observational time trend analysis, the
Figure1. LARC prescribing rate in general practices for registered women aged 15–44 years.
doi:10.1371/journal.pone.0092205.g001
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observed increases are related to specific time points surrounding
the introduction of QOF contraception indicators. Although we
adjusted to the Primary Care Trust level within our model, we did
not have information regarding local initiatives to improve access
to LARC. We also did not have information on the influence of
pharmaceutical companies over the same time frame through
marketing, promotion and provision of training on fitting of their
LARC products [33,34]. As with any ecological study design
evaluating the changes of a national policy the changes observed in
the time frame against the background trends may in part be
explained by the effect of concurrent efforts to increase LARC for
example as a result of social marketing.
During the study period, the commonest type of implant,
Implanon, was replaced by Nexplanon. The decrease in supply
and retraining required may have exerted a downward pressure on
the overall trend during the course of this changeover. Another
factor is that the Faculty for Reproductive and Sexual Health
published more stringent guidance on the training requirements
for GPs who inserted IUS/IUCD’s. These tighter monitoring
requirements may also have exerted a downward pressure on
prescribing that could have diluted the effect of our results of the
potential impact of the QOF itself.
Our study is also subject to ecological fallacy in that our
observed increase in practice level LARC prescribing may not
have increased specifically in those women given contraceptive
advice and recorded as having met the QOF contraceptive targets.
As our data from e-PACT excluded single-handed practices, we
cannot extrapolate findings to this group. This potentially
introduces a selection bias. However, the sensitivity analysis of
characteristics of our final sample of women aged 15 to 44 years
was nationally representative.
Policy implications and future research
recommendations
Recent research on contraceptive method choice among
European women found that the decision to use IUDs over other
methods is dictated by recommendations from the physician
rather than women [35]. The majority of unintended pregnancies
have been attributed to contraceptive failure and given that most
women in the UK access contraception from their GPs [36], a
switch to more clinically effective methods is likely to lead to a
substantial decrease in unintended pregnancies [37–40].
There may have been a wide variation between practices on
how QOF contraceptive care ‘quality’ indicators were achieved
that will affect the effectiveness of policy in future. Misconceptions
about side effects of many contraceptive methods including LARC
are common amongst UK general practitioners [41,42]. The
quality of contraceptive discussions can range from simply handing
over a leaflet to interactive in-depth discussion of each method
with the patient. Contraceptive decision making itself is a complex
process where women’s existing ideas and concerns affect their
acceptance of LARC [25,39]. Not all practices will have a trained
doctor or practice nurse who can administer or fit LARC methods.
GPs who are trained to fit IUDs or implants are more likely to
offer the method. There may have been an accompanying increase
in provision of LARC methods in sexual reproductive health
Table 1. Interrupted time-series analysis of LARC prescribing rates in general practices.
LARC (95% CI) Injectable (95% CI) Implant (95% CI) IUS (95% CI) IUCD (95% CI)
Time 0.99 (0.98,1.02) 0.98 (0.96,0.99) 1.64 (1.49,1.80) 1.19 (1.11,1.28) 1.04 (0.98,1.11)
QOF 0.99 (0.97, 1.02) 0.99 (0.96, 1.01) 1.20 (1.09, 1.32) 0.97 (0.90, 1.04) 1.02 (0.94, 1.10)
Time after QOF 1.04 (1.03, 1.06) 1.06 (1.04, 1.08) 1.34 (1.13, 1.58) 1.11 (0.97, 1.26) 0.99 (0.93, 1.05)
Seasonality
Apr-Jun – – – – –
Jul-Sep 0.97 (0.96, 0.99) 0.98 (0.97, 0.99) 0.95 (0.91, 1.00) 0.93 (0.89, 0.96) 0.95 (0.90, 1.01)
Oct-Dec 0.97 (0.95, 0.98) 0.98 (0.96, 0.99) 0.93 (0.88, 0.98) 0.91 (0.88, 0.95) 0.94 (0.89, 1.00)
Jan-Mar 0.98 (0.96, 0.99) 0.98 (0.97, 1.00) 1.02 (0.97, 1.07) 0.94 (0.91, 0.98) 1.01 (0.95, 1.07)
Socioeconomic status
Quintile 1 (the most affluent) – – – — —
Quintile 2 1.21 (1.05, 1.39) 1.30 (1.11, 1.51) 1.32 (1.08, 1.60) 1.02 (0.81, 1.29) 1.21 (0.91, 1.61)
Quintile 3 1.33 (1.14, 1.55) 1.49 (1.26, 1.75) 1.23 (0.98, 1.54) 0.75 (0.57, 0.97) 1.40 (1.01, 1.93)
Quintile 4 1.64 (1.40, 1.93) 1.81 (1.52, 2.16) 1.14 (0.91, 1.44) 0.65 (0.49, 0.85) 1.10 (0.79, 1.54)
Quintile 5 (the most deprived) 1.05 (0.88, 1.25) 1.04 (0.86, 1.25) 1.26 (0.96, 1.65) 0.43 (0.32, 0.59) 1.07 (0.74, 1.56)
Residence
Rural — — — — —
Urban 0.77 (0.66, 0.91) 0.84 (0.71, 0.99) 0.43 (0.35, 0.54) 0.55 (0.42, 0.72) 0.45 (0.32, 0.63)
White British (%) 1.01 (1.00, 1.01) 1.01 (1.00, 1.01) 1.00 (1.00, 1.01) 1.01 (1.00, 1.01) 1.00 (0.99, 1.00)
Female GP in the Practice
Without Female GP – – – – –
With Female GP 2.03 (1.82, 2.27) 1.81 (1.61, 2.04) 2.40 (1.95, 2.97) 1.81 (1.46, 2.25) 2.26 (1.76, 2.90)
Note: LARCs (Long-Acting Reversible Contraceptives), IUS (Intra-uterine system), IUCD (Intra-uterine copper devise).
`Model also controlled for regional variables (Primary Care Trust dummy variables), results not shown.
`As the linearity of the time trend was not met for implant and IUS outcomes, quadratic term for the time variable was added in the model.The beta coefficients are 0.91
(95% CI = 0.89, 0.94) for implant, and 0.97 (95% CI = 0.95, 0.99) for IUS.
doi:10.1371/journal.pone.0092205.t001
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clinics in the UK after QOF indicators were introduced due to
referrals by practices who do not provide LARC within the
practice. As our data did not have information for LARC items
issued by family planning and sexual health clinics, we might
underestimate the true impact of the QOF.
It should be noted that the definition of LARC for the purposes
of the QOF included injectable hormonal contraceptives. Inject-
able methods have a far lower continuation rate (50%) compared
with implants and IUDs (75 to 80%) and are not effective in
reducing unplanned pregnancy unlike other LARCs[3,4]. Argu-
ably these should not be offered as a LARC method and possibly
should even be dropped from the QOF definition. Economic and
resource implications for wider evaluation of this policy include
cost-effectiveness of the additional consultation time required to
achieve the QOF indicators, the training needs for LARC fitting in
general practices and use of contraceptive services in the
community.
These incentives targeted women already consulting for
contraceptive services, whose compliance, and risk of unplanned
pregnancy may differ from other groups of sexually active women
who do not take regular contraception, or those presenting for
termination counselling. In future, the target population could be
widened to include all women of child bearing age, which might
require call and recall systems rather than opportunistic counsel-
ling. Any such change would carry with it ethical and resource
considerations that would need to be carefully evaluated. The
discontinuation rate and the reason for discontinuation would be
important outcomes in assessing the quality of discussions given
that there may be improvement with continuations for those who
received in-depth discussions [43]. We therefore recommend
further research to investigate whether an increase in uptake of
LARC in primary care leads to a reduction of unintended
pregnancies in the long-term.
Conclusion
Our findings suggest that pay for performance incentives for
contraceptive counselling in primary care with women who are on
oral contraceptives or those requesting emergency contraception
have increased uptake of the more effective LARC methods.
Widening this policy has potential to result in a reduction in
unintended pregnancy but has resource, training and cost
implications. However, more information is needed on its
acceptability, sustainability, cost effectiveness and long term
benefit on reproductive outcomes including continuation rates
with LARC methods and impact on unplanned pregnancy.
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